Why the study?
When AF becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative atrial changes, but the response to sacubitril/valsartan in this setting is unclear.
Does sacubitril/valsartan improve symptoms and natriuretic peptide profiles in a patient with HFpEF and impaired ANP secretion due to long-standing persistent atrial fibrillation?
Does sacubitril/valsartan improve symptoms and natriuretic peptide profiles in a patient with HFpEF and impaired ANP secretion due to long-standing persistent atrial fibrillation?
Sacubitril/valsartan may be particularly effective in improving symptoms and natriuretic peptide profiles in HFpEF patients with impaired ANP secretion due to long-standing persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support sacubitril/valsartan in select HFpEF cases with AF-related ANP impairment; hypothesis-generating and requires prospective confirmation.
Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient’s symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.
No takes yet. Share an insight, caveat, or question.
Kurisu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: